Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States May 31, 2022
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity May 24, 2022
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference May 23, 2022
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 May 19, 2022
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference May 19, 2022
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency May 13, 2022
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 12, 2022
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 12, 2022
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights May 12, 2022
